98 results
Page 2 of 5
DEFA14A
EX-99.2
61cs fysey4ljo
21 Dec 20
Additional proxy soliciting materials
7:10am
8-K
EX-99.1
4fdwr qr0s8bsno0kxgb
21 Dec 20
Regulation FD Disclosure
7:04am
8-K
EX-99.2
91ace5ipouqzolfbgr
21 Dec 20
Regulation FD Disclosure
7:04am
S-3ASR
zsmz8ov7g4tc0aje4z
30 Apr 20
Automatic shelf registration
4:19pm
8-K
EX-99.1
p1cuswj
13 Jan 20
Regulation FD Disclosure
4:32pm
8-K
EX-99.3
u37eoq8e64rewabeqi3
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
424B5
ihe1u5q7fkrg
8 Nov 19
Prospectus supplement for primary offering
5:03pm
424B5
9ckd8xpr2
6 Nov 19
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
44p 88c73rj
31 Oct 19
Agios Reports Business Highlights and Third Quarter 2019 Financial Results
7:39am
8-K
EX-99.1
5iimxc9
28 Oct 19
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study ofAG-270, a MAT2A Inhibitor, in Patients withMTAP-Deleted Tumors
7:20am
8-K
e75cejwxbfhbrfiavao
28 Oct 19
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study ofAG-270, a MAT2A Inhibitor, in Patients withMTAP-Deleted Tumors
7:20am
8-K
EX-99.1
6hycbmqbr gqk30m
4 Sep 19
Other Events
5:05pm
8-K
EX-99.1
h6pjt6ph m5u
1 Aug 19
Agios Reports Business Highlights and Second Quarter 2019 Financial Results
7:29am